June 6, 2022
Olaris, Inc. to present novel myOLARIS™ assay detecting graft status in kidney transplant recipients at American Transplant Congress 2022 Meeting
Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, which aim to optimize treatments and outcomes for individual patients, is pleased to announce that the company’s study on the application of the myOLARIS-KTdx kidney transplant graft status score to transplant recipients has been selected for a poster presentation on June 6th at the upcoming American Transplant Congress (ATC) 2022 Annual Meeting, to be held June 4th-8th in Boston, Massachusetts. To view the poster presentation on video, visit https://youtu.be/QNJmbLaQ5Xc
June 1, 2022
Olaris, Inc. to present at American Transplant Congress 2022 Meeting
Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, which aim to optimize treatments and outcomes for individual patients, is pleased to announce that the company’s study on the application of the myOLARIS-KTdx kidney transplant graft status score to transplant recipients has been selected for a poster presentation on June 6th at the upcoming American Transplant Congress (ATC) 2022 Annual Meeting, to be held June 4th-8th in Boston, Massachusetts. To view the poster presentation, visit https://youtu.be/QNJmbLaQ5Xc .
May 12, 2022
Olaris, Inc to present non-invasive metabolic signature to detect over-immunosuppression in kidney transplant patients at International Transplant Science 2022 Meeting
Olaris, Inc is pleased to announce that the company’s study on the identification of a urine metabolic signature to detect over-immunosuppression in kidney transplant recipients has been selected for a presentation at the International Transplant Science (ITS) 2022 Annual Meeting, to be held May 15th-19th in Berlin, Germany. The presentation will describe the results of a multi-year collaboration between Olaris and Dr. Dirk Kuypers, Professor of Medicine and Chair of the Laboratory of Nephrology at the University of Leuven, to identify a biomarker for over-immunosuppression in kidney transplant recipients.
May 6, 2022
Olaris CEO Selected As 2022 EY Entrepreneur of the Year® New England Finalist
We are thrilled to announce that Olaris Founder and CEO Dr. Liz O'Day has been named a New England finalist for the EY Entrepreneur of the Year award. EY Entrepreneur Of The Year is one of the preeminent competitive business wards for entrepreneurs and leaders of high-growth companies.
April 8, 2022
Olaris, Inc. Announces Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Olaris, Inc. is pleased to announce that the company’s presentation on the identification of metabolic reprograming associated with CDK4/6 sensitivity and resistance has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research (AACR) annual meeting, to be held April 8th - 13th.
The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, will describe the recent results of a collaboration between Olaris and the Dana Farber Cancer Institute. Using a human breast cancer cell line model and isotope tracers, researchers determined that glucose metabolism was altered following treatment with two CDK4/6 inhibitors, palbociclib and abemaciclib. They also found that cells resistant to the drugs had alterations in different metabolic pathways, representing the first-ever evidence of metabolite signatures specific to two different CDK4/6 inhibitors.
View the presentation at https://youtu.be/nXBiGRcnqXk.
April 4, 2022
Olaris Data Scientist Chen Dong Featured in Mass Life Sciences Center Success Stories
Olaris Data Scientist Chen Dong was featured in the Success Stories page on the website of the Massachusetts Life Sciences Center (MLSC). Chen began as an MLSC-sponsored intern at Olaris in 2019, and his hard work has helped to drive Olaris' success, most recently with a publication on metabolite-based diagnostics for Parkinson's disease in men with LRRK2 mutations.
March 28, 2022
Olaris Grows Leadership Team with Key Executive Hires
Olaris, Inc. announced today that it has expanded its leadership team with key senior hires who will advance partnerships for and commercialization of its novel diagnostics with the potential to transform how diseases are diagnosed and treated.
Olaris' new additions include:
Russell Herndon as Chief Business Officer. Herndon has more than 30 years' experience leading innovative healthcare technology companies and initiatives.
Laura T. Housman as Chief Commercial Officer. Before joining Olaris, Housman spent more than 30 years driving access to innovation in healthcare focusing on diagnostics, therapeutics, and devices across a range of disease areas.
March 21, 2022
Olaris Announces Appointment of Shawn Ayube as Vice President of Operations
Olaris, Inc. announced today the appointment of Shawn Ayube, a 20-year veteran in the biopharmaceutical industry, as Vice President of Operations.
In his new role, Ayube will be in charge of driving scalability across the organization and lead the effort to strategically enhance Olaris’ R&D capabilities as well as steering talent management and leadership development.
March 15, 2022
Olaris CEO Dr. Liz O'Day Serves as Visiting Scientist at National Heart, Lung, and Blood Institute
Olaris Founder and CEO Dr. Liz O'Day is serving today as a virtual visiting scientist at the National Heart, Lung, and Blood Institute Biochemistry and Biophysics Center. Dr. O'Day will give a presentation on how machine learning and artificial intelligence can be combined with NMR and metabolomics to better understand the biology underlying Parkinson's Disease.
March 8, 2022
Olaris Announces Appointment of Dr. Keri Sheehan as Director of Communications and Project Management
Olaris, Inc. announced today the appointment of Dr. Keri Sheehan as Director of Communications and Project Management. Dr. Sheehan holds a Ph.D. in Immunology from University of Pennsylvania, where she worked on the molecular dynamics of the cytoskeleton in natural killer cells, and completed postdoctoral fellowships at Harvard Medical School and UMass Chan Medical School. She has over 5 years of experience in improving research communications and scientific journal processes.
March 4, 2022
Olaris CEO Dr. Liz O'Day Presents at Horasis USA Meeting 2022
Olaris Founder and CEO Dr. Liz O'Day presents today at the Horasis USA Meeting in a panel on female entrepreneurs in tech.
February 28, 2022
Olaris CEO Dr. Liz O'Day Serves as Mentor for Boston Business Journal BizWomen Mentoring Monday
Olaris Founder and CEO Dr. Liz O'Day served as a mentor today in the 9th annual Boston Business Journal Mentoring Monday program. The one-of-a-kind virtual event brought together women in business for a networking and fun in a fast-paced coaching atmosphere. The Boston event featured keynote speaker Michelle Wu, 3 panel sessions, and breakout mentoring sessions.
February 8, 2022
Olaris CEO Presents at Truist Securities Life Sciences AI Symposium - Biotech & Tools
Olaris Founder and CEO Dr. Elizabeth O'Day will present virtually at the Truist Securities AI Symposium – Biotech & Tools. The symposium will take place virtually on Tuesday, March 1, 2022.
The presentation by Dr. O'Day will discuss the unique combination of metabolomics and machine learning used by Olaris to develop diagnostics to empower patients that they have the right diagnosis and are on the right treatment path.
In addition to speakers, the symposium also features 3 panels, with focuses on applying AI to synthetic biology and therapeutics, utilizing deep learning and quantum physics for drug development, and integrated platforms for AI-based drug discovery. The keynote address will feature a discussion by Pfizer covering the use of AI and pharma in development of the COVID vaccine. A full agenda for the event can be found at: https://www.openexc.com/wp-content/uploads/2022/02/AI-Symposium-Agenda-2.24.pdf .
February 3, 2022
Olaris Announces Appointment of Dr. Jifang Zhao as Senior Data Scientist
Olaris, Inc. announced today the appointment of Dr. Jifang Zhao as a Senior Data Scientist on the Data Science team. Jifang has years of expertise in statistics and machine learning and holds a Ph.D. and a Masters in Statistics from Virginia Commonwealth University, where he developed novel methods for processing large-scale, high-dimensional data from neuroimaging.
January 18, 2022
Olaris Partners with Thermo Fisher on Metabolomics Diagnostic Assay for Immune Response in Transplant Recipients
Olaris and Thermo Fisher Scientific are partnering to evaluate the feasibility of a machine learning and metabolomics–based diagnostic panel to assess risk of developing complications from overimmunosuppression in kidney transplant recipients
December 6, 2021
Olaris Presenting at SABCS 2021: Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients
Olaris presented new data on the identification of metabolic signatures in matched plasma and serum samples associated with tumor proliferation in early-stage breast cancer (eBC) patients treated with Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) at the upcoming San Antonio Breast Cancer Symposium® to be held December 7-10, 2021. The presentation, conducted in collaboration with Dr. Cynthia Ma, Professor of Medicine, Division of Oncology at Washington University in St. Louis, highlights the use of Olaris’ BoR platform to identify metabolic signatures associated with tumor proliferation, an indicator of treatment resistance, in eBC patients treated with CDK4/6i.
October 11, 2021
Olaris Attending HLTH 2021 in Boston with Microsoft for Startups
Find us at HLTH 2021 in Boston to connect and learn more about our to our pioneering metabolomics platform and machine learning algorithms that produce Biomarkers of Response which can differentiate drug responders from non-responders and ensure optimal treament. We are building our BoR pipeline across oncology, transplant, and neurodegeneration. Contact MfSatHLTH@microsoft.com to set up a time.
October 8, 2021
Women In Biopharma: Seven women in life sciences weigh in on the challenges facing the industry
This week, the Business Journal featured a handful of Boston-area women in the industry, both established leaders as well as those who are just breaking onto the scene, at its Women Who Lead in Life Sciences event. In the following pages, they discuss their careers, the challenges facing their industry and what needs to be done to promote women in the male-dominated field.
September 30, 2021
Olaris Appoints Nephrology and Transplant Expert Dr. Dirk Kuypers to SAB
Dr. Kuypers is Professor of Medicine and Chair of the Laboratory of Nephrology at the University of Leuven, Belgium. He is also the Head of the Department of Nephrology and Director of the Renal Transplantation Program at the University Hospitals Leuven, Belgium. Dr. Kuypers’ clinical and translational research has spanned renal allograft surveillance using protocol biopsies and biomarkers of allograft status to pre-clinical and clinical immunosuppressive therapy development. He founded the Leuven Renal Allograft Biobank, which contributes prospectively collected biological samples and clinical data to translational studies in kidney transplantation.
August 2, 2021
Olaris CEO Joins New AACR Working Group on Cancer Evolution
Why is cancer so hard to treat? How can we overcome resistance? Cancer is an everchanging disease-and many of the greatest treatment challenges are driven by clonal evolution. We must adapt to keep up!
In a great step, the AACR has formed the new Cancer Evolution working group, with Olaris CEO Dr. Liz O'Day on the Steering Committee. Co-chaired by Frank Laukien, CEO of Bruker, and Charles Swanton of the Francis Crick and UCL Cancer Institutes, this group of experts will translate cutting-edge research into new diagnostic, therapeutic, and prevention strategies.
A new way of treating cancer is coming, and biomarkers will be the guide!
July 13, 2021
Microsoft's Tom Davis: Dr. Liz O'Day brings scientific rigor to the business of precision medicine
From the laboratory to the boardroom, Tom Davis discovers how Dr. Liz O’Day applied her science career to founding biotech startup Olaris in the latest "Meet The Innovators" series.
July 9, 2021
Olaris CEO Recognized as Innovative Female Founder in Healthcare by Microsoft for Startups
When an estimated 7% of all health & life science startups are started by women, these five female founders are leading some of the most innovative companies in transforming healthcare services. Read more from Sally Ann Frank on The Record about how their startup ideas led to fast-moving businesses.
June 10, 2021
Olaris CEO Selected As 2021 Entrepreneur of the Year New England Finalist
We are honored to have Dr. Liz O'Day recognized among so many unstoppable business leaders in New England as one of the Finalists for EY Entrepreneur of The Year! For 35 years, the award has recognized game-changing entrepreneurs - those who have ushered in innovation throughout their careers and who are disrupting industries with each step they take.
June 3, 2021
Olaris BoR Technology on C-Sessions with Randall Broad
Olaris CEO and Founder Dr. Liz O'Day had the opportunity to share the origin of BoR technology with C-sessions and describe how our BoRs can be used as a tool to determine which treatment is best for each patient- even before they start therapy. Listen below to learn how Olaris BoRs in oncology can empower patients and providers to be confident in their treatment.
May 12, 2021
Olaris Welcomes Dr. Leonardo Rodrigues as VP of Artificial Intelligence and Machine Learning
In his role, Dr. Rodrigues will lead the acceleration of Olaris’ data strategy for the continued development of novel diagnostics with the potential to transform how diseases are diagnosed and treated. He will also provide critical insight enabling Olaris to streamline its technology for companion diagnostic development with biopharma partners in clinical trials.
May 2, 2021
Boston Business Journal: Olaris founder Liz O'Day works to make personalized medicine a reality
Liz O'Day has founded a for-profit biotech company, a nonprofit organization and is working hard to help the world return not only to 'some version of normal but hopefully even better.'
April 9, 2021
Olaris Announces Presentation on Metabolic Biomarkers of Response in Advanced GIST at American Association for Cancer Research (AACR) 2021 Annual Meeting
Olaris is pleased to announce the company’s presentation on the identification of metabolic signatures in plasma samples associated with therapeutic response in metastatic gastrointestinal stromal tumors (GIST) has been selected for poster presentation at the upcoming 2021 American Association for Cancer Research (AACR) annual meeting, to be held virtually April 10th - 15th.
The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, highlights the use of Olaris’ BoR platform to identify metabolic signatures correlated with overall survival and to predict response or resistance to treatment in patients with advanced GIST.
March 31, 2021
Dr. Elizabeth O'Day Selected to Join the Biological Magnetic Resonance Bank Advisory Board
Dr. O'Day is thrilled to join the BMRB advisory board to help expand the internationally renowned repository for biomolecular NMR data. Dr. O'Day will serve as a metabolomics and biotech advisor as BRMB develops additional content and tools to serve users of the repository.
March 22, 2021
Olaris Joins Microsoft for Startups
As the newest member of of the technology leader's global program aimed at helping startups scale, Olaris will be steamlining BoR development in immune response, neurodegeneration, and oncology. Olaris will also expand collaboration opportunities within biotechnology and healthcare through Microsoft's global partnership ecosystem.
March 3, 2021
Olaris CEO Featured on Catalyst Health Innovation Summit Panel
Dr. O'Day was joined by industry experts and thought leaders Joshua Weiner, Healthcare Strategy at Facebook, and Dr. Martin-Immanuel Bittner, CEO of Arctoris, to discuss biotech innovations during the pandemic and to share their insights on the future of healthcare during their panel at Cataylst HIF 2021.
February 16, 2021
World-leading Breast Cancer Oncologists Cynthia Ma MD, PhD and Massimo Cristofanilli, MD to Join Olaris Scientific and Medical Advisory Board
Olaris has appointed Dr. Cynthia Ma of Washington University in St. Louis and Dr. Massimo Cristofanilli from Northwestern Medicine to its Scientific Advisory Board and Medical Advisory Board. Dr. Ma and Dr. Cristofanilli will provide guidance on commercializing Olaris’ successful research identifying metabolic signatures for response to CDK4/6 inhibitors and building a pipeline of clinically differentiated, high-value diagnostic solutions.
January 20, 2021
Dr. Elizabeth O'Day, Olaris CEO, and Dr. Mike Pellini, Managing Director of Section 32 speak on BC panel
Dr. Elizabeth O'Day and Dr. Mike Pellini discuss how far biotechnology has come in the last decade and share their insights on how robust diagnostics will usher in the future of precision medicine. Watch their panel in the recap below.
November 13, 2020
Scientific American Top 10 Emerging Tech of 2020: Olaris CEO Discusses Microneedles
Read Olaris CEO Dr. Elizabeth O'Day's article on how microneedles could enable painless injections and blood draws in Scientific Americans Top 10 Emerging Technologies of 2020.
November 3, 2020
Olaris CEO Featured in Authority Magazine's Female Disruptors Series
"My baseline for whether disruption is ‘good’ is thinking about whether the change in the industry will have a genuinely positive impact on people’s lives. Of course, this is a subjective measure, but in the case of Olaris, you can make the strong argument that our platform for determining which patients will benefit from a specific therapy will improve the lives of millions." - Dr. Elizabeth O'Day as interviewed in Authority Magazine's Female Disruptors series aimed to feature women bringing radical change to their industry.
October 30, 2020
Olaris Presents At BU Questrom's Annual Health and Life Sciences Conference
Dr. Elizabeth O'Day discussed how Olaris leverages metabolomics and machine learning through our Biomarkers of Response platform to determine the most effective therapies for patients - providing the right drug, to the right patient, at the right time.
October 26, 2020
Olaris Honored to Recieve BostInno's 50 on Fire 2020 Award
Olaris was selected for BostInno's 50 on Fire award for our Biomarkers of Response platform to determine whether a patient will respond to certain drugs or treatments for certain types of diseases. Our technology was recognized by STAT for developing biomarker-based tests over the past year for metastatic breast cancer, metastatic gastrointestinal stromal tumors, Parkinson’s Disease and for immunosuppressive drugs given before a kidney transplant.
October 20, 2020
Olaris Featured in Node by Slush Event with Astrazeneca
Olaris joined Astrazeneca on October 20th for the first of two digital engagement events with Slush, focusing on ‘Healthcare of the future – a roadmap towards collaborative value creation’ to present our unique Biomarkers of Response platform.
October 16, 2020
Olaris Presents at Groundbreaking Cancer & Evolution Symposium
Dr. Elizabeth O'Day joined influential scientists in cancer biology and evolutionary biology, including Azra Raza, George Church, Adelene Perkins, Frank Laukien, and Denis Noble, at the first meeting of the Cancer and Evolution Symposium to present the Olaris BoR platform for assessing breast cancer patient response to CDK4/6 inhibitors to improve outcomes.
View Dr. O'Day's talk below.
September 29, 2020
Olaris CEO Panelist Speaker at The Digital Clinical Biomarkers & World CDx Summit
Dr. Elizabeth O'Day participated in an excellent panel discussion on Women and Diversity in Precision Medicine with Dr. Maria C.M. Orr (Head of Precision Medicine for Biopharmaceuticals at Astrazeneca) and Nina Green (VP and GM of Companion Diagnostics at Agilent Technologies) at the Clinical Biomarkers and World CDx Summit in September.
Increasing diversity in precision medicine must be deliberate, and the "Yes And, No But" challenge can do just that. When accepting an opportunity, suggest a colleague or individual who you think would also benefit from and contribute to the experience but may not have been offered the opportunity. If you are unable to accept, suggest someone who is less likely to be invited to go in your place!
September 23, 2020
Olaris CEO Selected for Boston Business Journals 40 under 40
Dr. Elizabeth O’Day was selected for the Boston Business Journals 40 under 40 award which highlights the best and brightest professionals in the Greater Boston area.